Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00186823 · ClinicalTrials.gov registry record · Phase 3
Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies
A Phase 3 study of Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML), sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 57
- Enrollment target
- 1
- Study location
NCT00186823: Completed Phase 3 study of Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML), sponsored by St. Jude Children's Research Hospital.
NCT00186823 is a Phase 3 study of Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML) that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 57 participants, below the 83-participant average among 19 other Myelodysplastic Syndrome (MDS) trials with a reported enrollment target (31% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00186823, a Phase 3 study of Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML), has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 57 participants
- Enrollment target
- 1
- Study location
Study Summary
Blood and marrow stem cell transplant has improved the outcome for patients with high-risk hematologic malignancies. However, most patients do not have an appropriate HLA (immune type) matched sibling donor available and/or are unable to identify an acceptable unrelated HLA matched donor through the registries in a timely manner. Another option is haploidentical transplant using a partially matched family member donor. Although haploidentical transplant has proven curative in many patients, this procedure has been hindered by significant complications, primarily regimen-related toxicity including graft versus host disease (GVHD) and infection due to delayed immune reconstitution. These can, in part, be due to certain white blood cells in the graft called T cells. GVHD happens when the donor T cells recognize the body tissues of the patient (the host) are different and attack these cells. Although too many T cells increase the possibility of GVHD, too few may cause the recipient's immune system to reconstitute slowly or the graft to fail to grow, leaving the patient at high-risk for significant infection. This research project will investigate the use of particular pre-transplant conditioning regimen (chemotherapy, antibodies and total body irradiation) followed by a stem cell infusion from a "mismatched" family member donor. Once these stem cells are obtained they will be highly purified in an effort to remove T cells using the investigational CliniMACS stem cell selection device. The primary goal of this study will be to determine the rate of neutrophil and platelet engraftment, as well as the degree and rate of immune reconstitution in the first 100 days posttransplant for patients who receive this study treatment. Researchers will also study ways to decrease complications that may occur with a transplant from a genetically mismatched family donor.
Conditions Studied
Interventions
- PROCEDURE Stem Cell Transplantation
- DEVICE Miltenyi Biotec CliniMACS
- DRUG TBI, systemic chemotherapy and antibodies as follows:
Study Locations (1)
Tennessee
- St. Jude Children's Research Hospital - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2002-03 |
| Est. Completion | 2009-01 |
| Phase | Phase 3 |
What the finished NCT00186823 record still lists
NCT00186823 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 83-participant average among 19 other Myelodysplastic Syndrome (MDS) trials with a reported enrollment target (31% lower).
The record links to 7 conditions, with Myelodysplastic Syndrome (MDS) appearing as the primary indexed condition, and to 3 interventions - of which Stem Cell Transplantation is the first listed.
NCT00186823 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT00186823 about?
NCT00186823 is a clinical study titled "Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies". Blood and marrow stem cell transplant has improved the outcome for patients with high-risk hematologic malignancies. However, most patients do not have an appropriate HLA (immune type) matched sibling donor available and/or are unable to identify an acceptable unrelated HLA matched donor through the...
What is the current status of trial NCT00186823?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 57 participants. The study started on 2002-03. Estimated completion is 2009-01.
What conditions does trial NCT00186823 study?
This clinical trial studies the following conditions: Myelodysplastic Syndrome (MDS), Juvenile Myelomonocytic Leukemia (JMML), Lymphoma, Non-Hodgkin (NHL), Leukemia, Acute Lymphocytic (ALL), Leukemia, Myeloid, Acute(AML).
What interventions are being tested in trial NCT00186823?
The interventions under investigation include: Stem Cell Transplantation (PROCEDURE), Miltenyi Biotec CliniMACS (DEVICE), TBI, systemic chemotherapy and antibodies as follows: (DRUG).
Who is sponsoring clinical trial NCT00186823?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00186823 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndrome (MDS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00186823's enrollment target sits among peer trials
57 8th of 19 higher than 12 of 19 other Myelodysplastic Syndrome (MDS) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myelodysplastic Syndrome (MDS) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
ACTIVE NOT RECRUITING · Phase 3
-
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
RECRUITING · Phase 1
-
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 1
-
Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics
RECRUITING · Phase 1
-
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
RECRUITING · Phase 2
-
A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia